Survival Among Patients with Adenocarcinoma of the Pancreas: A Population-based Study (United States)
- 301 Downloads
The purpose of the current study was to evaluate survival of patients diagnosed in California with adenocarcinoma of the pancreas by demographic and tumor-related factors.
Through the California Cancer Registry (CCR) we identified all California residents diagnosed with invasive pancreatic adenocarcinoma between 1994 and 2000. Demographic, tumor and treatment information was extracted from the CCR, and socioeconomic status (SES) was assigned based on census block group of residence.
A total of 10,612 eligible patients were identified of whom 1674 (15.8%) underwent surgical resection. Patients of lower SES were less likely to undergo resection and somewhat less likely to survive. Median survival was 3.5 months for patients who were not resected and 13.3 months for those who underwent resection. Adjuvant therapy was associated with a decreased risk of death among patients who underwent resection.
This study is the largest population-based study to date to explore survival from pancreatic cancer among all age groups in a racially diverse population. Median survival was shorter than that reported from other series. Race/ethnicity did not have a significant effect on survival. However patients residing in poor neighborhoods were less likely to undergo resection and somewhat less likely to survive this disease.
KeywordsPancreatic neoplasms Survival Social class Registries
The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885, the National Cancer Institute’s Surveillance, Epidemiology and End Results Program, and the Centers for Disease Control and Prevention National Program of Cancer Registries. The ideas and opinions expressed herein are those of the author and endorsement by the State of California, Department of Health Services, the National Cancer Institute and the Centers for Disease Control and Prevention is not intended nor should be inferred.
- 1.Tucker T, Howe H, Weir H (1999) Certification for population-based cancer registries. J Registry Manage 26:24–27Google Scholar
- 2.Stewart S, Glaser S, Horn-Ross P, West D (1993) SEER study of methods to classify Hispanic cancer patients (Final Report: Contract N01-CN-05224). In Edition Union City, CA: Northern California Cancer CenterGoogle Scholar
- 3.Kwong S, Perkins C, Morris C et al. (2001) Cancer in California: 1988–1999. In Edition Sacramento, CA: California Department of Health Services, Cancer Surveillance SectionGoogle Scholar
- 4.Shambaugh E, Ries L, Young J et al. (1992) SEER Extent of Disease – 1988 Codes and Coding InstructionsGoogle Scholar
- 5.Seiffert J, ed. (1993) SEER Program: comparative staging guide for cancer, version 1.1. National Cancer InstituteGoogle Scholar
- 6.Young J, Roffers S, Ries L et al. (2001) SEER Summary Staging Manual – 2000. Codes and Coding Instructions, National Cancer Institute, Bethesda, MDGoogle Scholar
- 7.Percy C, Van Holten V, Muir C (eds) (1990) International Classification of Diseases for Oncology, 2nd Edition. Geneva: World Health OrganizationGoogle Scholar
- 9.Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
- 11.Cox D (1972) Regression models and life tables. J R Stat Soc 34:187–202Google Scholar
- 14.Warren JL, Klabunde CN, Schrag D et al. (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18Google Scholar